PMID- 16042776
OWN - NLM
STAT- MEDLINE
DCOM- 20060421
LR  - 20181113
IS  - 1471-2172 (Electronic)
IS  - 1471-2172 (Linking)
VI  - 6
DP  - 2005 Jul 22
TI  - Inhibition of chemokine expression in rat inflamed paws by systemic use of the 
      antihyperalgesic oxidized ATP.
PG  - 18
AB  - BACKGROUND: We previously showed that local use of periodate oxidized ATP (oATP, 
      a selective inhibitor of P2X7 receptors for ATP) in rat paw treated with Freund's 
      adjuvant induced a significant reduction of hyperalgesia Herein we investigate 
      the role of oATP, in the rat paws inflamed by carrageenan, which mimics acute 
      inflammation in humans. RESULTS: Local, oral or intravenous administration of a 
      single dose of oATP significantly reduced thermal hyperalgesia in hind paws of 
      rats for 24 hours, and such effect was greater than that induced by diclofenac or 
      indomethacin. Following oATP treatment, the expression of the pro-inflammatory 
      chemokines interferon-gamma-inducible protein-10 (IP-10), mon ocyte 
      chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) within the inflamed 
      tissues markedly decreased on vessels and infiltrated cells. In parallel, the 
      immunohistochemical findings showed an impairment, with respect to the untreated 
      rats, in P2X7 expression, mainly on nerves and vessels close to the site of 
      inflammation. Finally, oATP treatment significantly reduced the presence of 
      infiltrating inflammatory macrophages in the paw tissue. CONCLUSION: Taken 
      together these results clearly show that oATP reduces carrageenan-induced 
      inflammation in rats.
FAU - Fulgenzi, Alessandro
AU  - Fulgenzi A
AD  - Universita degli Studi di Milano, Istituto di Patologia Generale, via Mangiagalli 
      31, 20133, Milano, Italy. mariaelena.ferrero@unimi.it.
FAU - Dell'Antonio, Giacomo
AU  - Dell'Antonio G
FAU - Foglieni, Chiara
AU  - Foglieni C
FAU - Dal Cin, Elena
AU  - Dal Cin E
FAU - Ticozzi, Paolo
AU  - Ticozzi P
FAU - Franzone, Jose S
AU  - Franzone JS
FAU - Ferrero, Maria Elena
AU  - Ferrero ME
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050722
PL  - England
TA  - BMC Immunol
JT  - BMC immunology
JID - 100966980
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokines)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Cxcl10 protein, rat)
RN  - 0 (Interleukin-8)
RN  - 0 (P2RX7 protein, human)
RN  - 0 (P2rx7 protein, rat)
RN  - 0 (Purinergic P2 Receptor Antagonists)
RN  - 0 (Receptors, Purinergic P2)
RN  - 0 (Receptors, Purinergic P2X7)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 54970-91-1 (2',3'-dialdehyde ATP)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - 9000-07-1 (Carrageenan)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adenosine Triphosphate/administration & dosage/*analogs & 
      derivatives/pharmacology/physiology/therapeutic use
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Analgesics, Non-Narcotic/administration & dosage/pharmacology/*therapeutic use
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/pharmacology/*therapeutic use
MH  - Carrageenan/toxicity
MH  - Chemokine CCL2/biosynthesis/genetics
MH  - Chemokine CXCL10
MH  - Chemokines/*biosynthesis/genetics
MH  - Chemokines, CXC/biosynthesis/genetics
MH  - Diclofenac/administration & dosage/therapeutic use
MH  - Disease Models, Animal
MH  - Hindlimb
MH  - Hot Temperature
MH  - Hyperalgesia/chemically induced/*drug therapy/etiology
MH  - Indomethacin/administration & dosage/therapeutic use
MH  - Injections, Intravenous
MH  - Interleukin-8/biosynthesis/genetics
MH  - Macrophages/drug effects
MH  - Male
MH  - Purinergic P2 Receptor Antagonists
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Purinergic P2/biosynthesis/genetics
MH  - Receptors, Purinergic P2X7
MH  - Single-Blind Method
PMC - PMC1190175
EDAT- 2005/07/27 09:00
MHDA- 2006/04/25 09:00
PMCR- 2005/07/22
CRDT- 2005/07/27 09:00
PHST- 2005/03/22 00:00 [received]
PHST- 2005/07/22 00:00 [accepted]
PHST- 2005/07/27 09:00 [pubmed]
PHST- 2006/04/25 09:00 [medline]
PHST- 2005/07/27 09:00 [entrez]
PHST- 2005/07/22 00:00 [pmc-release]
AID - 1471-2172-6-18 [pii]
AID - 10.1186/1471-2172-6-18 [doi]
PST - epublish
SO  - BMC Immunol. 2005 Jul 22;6:18. doi: 10.1186/1471-2172-6-18.